

Unless otherwise defined herein, capitalised terms in this announcement shall have the same meanings as those defined in the prospectus dated August 31, 2018 (the “**Prospectus**”) issued by the Hua Medicine (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. Potential investors should read the Prospectus for detailed information about the Company, the Hong Kong Public Offering and the International Offering described below before deciding whether or not to invest in the Shares thereby offered.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or any state securities laws of the United States and may be offered and sold (a) in the United States only to persons who are both “*Qualified Institutional Buyers*” and “*Qualified Purchasers*” in reliance on Rule 144A or another exemption from, or in a transaction not subject to, registration under the U.S. Securities Act and (b) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act. The Company has not intended and does not intend to make any public offer of securities in the United States. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial statements. No registration has been or will be made under the United States Investment Company Act of 1940.

In connection with the Global Offering, Goldman Sachs (Asia) L.L.C. as stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, to the extent permitted by the applicable laws of Hong Kong or elsewhere, may over-allocate or effect transactions with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules, as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilizing action cannot be taken to support the price of the Shares for longer than the stabilization period which begins on the Listing Date and is expected to expire on Friday, October 5, 2018 being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.



**HUA MEDICINE**

**華領醫藥**

*(Incorporated in the Cayman Islands with limited liability)*

## **GLOBAL OFFERING**

- Number of Offer Shares under the Global Offering** : **104,756,000 Shares (subject to the Over-allotment Option)**
- Number of Hong Kong Offer Shares** : **10,476,000 Shares (subject to reallocation)**
- Number of International Offer Shares** : **94,280,000 Shares (subject to reallocation and the Over-allotment Option)**
- Maximum Offer Price** : **HK\$9.28 per Offer Share, plus brokerage of 1%, SFC transaction levy of 0.0027%, and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)**
- Nominal value** : **US\$0.001 per Share**
- Stock code** : **2552**

### *Joint Sponsors*

**Goldman Sachs**

**CLSA** A CITIC Securities Company

### *Joint Global Coordinators and Joint Bookrunners*

**Goldman Sachs**

**CLSA** A CITIC Securities Company

 **UBS**

### *Joint Lead Managers*

**Goldman Sachs**

**CLSA** A CITIC Securities Company

 **UBS**

 **國泰君安國際**  
GUOTAI JUNAN INTERNATIONAL

Application has been made by the Company to the Listing Committee of the Stock Exchange for the listing of, and permission to deal in, the Shares in issue and to be issued pursuant to the Global Offering (including any additional Shares which may be issued pursuant to the exercise of the Over-allotment Option and any option that may be granted under Post-IPO Share Option Scheme). Dealings in the Shares on the Main Board are expected to commence at 9:00 a.m. on Friday, September 14, 2018.

The Global Offering comprises the Hong Kong Public Offering of 10,476,000 Shares (subject to reallocation), representing approximately 10% of the total Offer Shares, and the International Offering of an aggregate of 94,280,000 Shares, subject to reallocation and the Over-allotment Option), representing approximately 90% of the total Offer Shares. The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to adjustment as described in the section headed “Structure of the Global Offering” in the Prospectus.

The Company is expected to grant the Over-allotment Option to the International Underwriters, exercisable by the Stabilization Manager (for themselves and on behalf of the International Underwriters) at any time from the Listing Date until Friday, October 5, 2018, being the 30th day from the last day for lodging applications under the Hong Kong Public Offering, to require the Company to allot and issue up to an aggregate of 15,713,000, additional Offer Shares representing not more than 15% of the number of Offer Shares initially being offered under the Global Offering, at the Offer Price to solely cover over-allocations in the International Offering, if any.

In the event the Over-allotment Option is exercised, an announcement will be made by the Company on the Company’s website at [www.huamedicine.com](http://www.huamedicine.com) and the website of the Hong Kong Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk).

Subject to the granting of the approval for listing of, and permission to deal in, the Shares (including any Shares which may be issued pursuant to the exercise of the Over-allotment Option and any option that may be granted under Post-IPO Share Option Scheme) on the Stock Exchange and compliance with the stock admission requirements of HKSCC, the Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the Shares on the Stock Exchange or such other date as may be determined by HKSCC. Settlement of transactions between participants of the Stock Exchange is required to take place in CCASS on the second Business Day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made to enable the Shares to be admitted into CCASS.

The Offer Price will not be more than HK\$9.28 per Offer Share and is currently expected to be not less than HK\$8.28 per Offer Share, unless otherwise announced before the last day for lodging applications under the Hong Kong Public Offering. Applicants for the Hong Kong Offer Shares are required to pay, on application, the maximum Offer Price of HK\$9.28 per Offer Share together with brokerage of 1.0%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%. If the Offer Price as finally determined is less than the maximum Offer Price of HK\$9.28 per Offer Share (excluding brokerage, SFC transaction levy and the Stock Exchange trading fee thereon), or if the conditions of the Hong Kong Public Offering are not fulfilled in accordance with the section headed “Structure of the Global Offering — Conditions of the Hong Kong Public Offering” in the Prospectus or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy and the Stock Exchange trading fee, will be refunded, without interest or the cheque or banker’s cashier order will not be cleared.

**Applications for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus, the Application Forms and the designated website ([www.hkeipo.hk](http://www.hkeipo.hk)) in relation to the HK eIPO White Form.** Applicants who would like to have the allotted Hong Kong Offer Shares registered in their own names should either (i) complete and sign the **WHITE** Application Forms, or (ii) submit applications online through the designated website of the **HK eIPO White Form Service Provider** at [www.hkeipo.hk](http://www.hkeipo.hk) under the **HK eIPO White Form** service. Applicants who would like to have the allotted Hong Kong Offer Shares registered in the name of HKSCC Nominees and deposited directly into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participants maintained in CCASS should either (i) complete and sign the **YELLOW** Application Forms, or (ii) give **electronic application instructions** to HKSCC via CCASS.

Copies of the Prospectus, together with the **WHITE** Application Form, may be obtained during normal business hours from 9:00 a.m. on Friday, August 31, 2018, until 12:00 noon on Wednesday, September 5, 2018 from:

1. the following addresses of certain Hong Kong Underwriters:

Goldman Sachs (Asia) L.L.C.  
59/F, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

CLSA Limited  
18/F, One Pacific Place, 88 Queensway, Hong Kong

UBS AG Hong Kong Branch  
52/F, Two International Finance Centre, 8 Finance Street, Central, Hong Kong

Guotai Junan Securities (Hong Kong) Limited  
27/F, Low Block, Grand Millennium Plaza, 181 Queen’s Road Central, Hong Kong

2. any of the following branches of the receiving bank:

Wing Lung Bank Limited

	<b>Branch Name</b>	<b>Address</b>
<b>Hong Kong Island</b>	Head Office	45 Des Voeux Road Central
	Johnston Road Branch	118 Johnston Road
	Kennedy Town Branch	28 Catchick Street
<b>Kowloon</b>	Mong Kok Branch	Basement, Wing Lung Bank Centre, 636 Nathan Road
	Tsim Sha Tsui Branch	4 Carnarvon Road
<b>New Territories</b>	Tsuen Wan Branch	251 Sha Tsui Road

Copies of the Prospectus, together with the **YELLOW** Application Form, may be obtained during normal business hours from 9:00 a.m. on Friday, August 31, 2018 until 12:00 noon on Wednesday, September 5, 2018 from the Depository Counter of HKSCC at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong or your stockbroker, who may have such Application Forms and the Prospectus available.

The **WHITE** or **YELLOW** Application Form completed in accordance with the instructions printed thereon, together with a cheque or banker's cashier order payable to "Wing Lung Bank (Nominees) Limited — Hua Medicine Public Offer" attached should be deposited in the special collection boxes provided at any of the branches referred to above, at the following times:

Friday, August 31, 2018 — 9:00 a.m. to 5:00 p.m.  
Saturday, September 1, 2018 — 9:00 a.m. to 1:00 p.m.  
Monday, September 3, 2018 — 9:00 a.m. to 5:00 p.m.  
Tuesday, September 4, 2018 — 9:00 a.m. to 5:00 p.m.  
Wednesday, September 5, 2018 — 9:00 a.m. to 12:00 noon

Applicants applying by **HK eIPO White Form** may submit applications through the **HK eIPO White Form** service at [www.hkeipo.hk](http://www.hkeipo.hk) (24 hours daily, except on the last application day) from 9:00 a.m. on Friday, August 31, 2018 until 11:30 a.m. on Wednesday, September 5, 2018 or such later time as described in the section headed "How to Apply for the Hong Kong Public Offer Shares — 10. Effect of Bad Weather on the Opening of the Application Lists" in the Prospectus (24 hours daily, except on the last application day).

CCASS Clearing/Custodian Participants can input **electronic application instructions** at the following times on the following dates:

Friday, August 31, 2018 — 9:00 a.m. to 8:30 p.m.  
Saturday, September 1, 2018 — 8:00 a.m. to 1:00 p.m.  
Monday, September 3, 2018 — 8:00 a.m. to 8:30 p.m.  
Tuesday, September 4, 2018 — 8:00 a.m. to 8:30 p.m.  
Wednesday, September 5, 2018 — 8:00 a.m. to 12:00 noon

*Note:*

- (1) The times in this sub-section are subject to change as HKSCC may determine from time to time with prior notification to CCASS Clearing/Custodian Participants and/or CCASS Investor Participants.

CCASS Investor Participants can input **electronic application instructions** from 9:00 a.m. on Friday, August 31, 2018 until 12:00 noon on Wednesday, September 5, 2018 (24 hours daily, except on Wednesday, September 5 the last application day).

The latest time for inputting your **electronic application instructions** will be 12:00 noon on Wednesday, September 5, 2018, the last application day or such later time as described in the section headed “Effect of Bad Weather on the Opening of the Application Lists” in the Prospectus.

Please refer to the sections headed “Structure of the Global Offering” and “How to Apply for the Hong Kong Offer Shares” in the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

The Company expects to publish the announcement on the final Offer Price, the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares under the Hong Kong Public Offering (i) in the South China Morning Post (in English); (ii) in the Hong Kong Economic Journal (in Chinese); (iii) on the website of the Hong Kong Stock Exchange ([www.hkexnews.hk](http://www.hkexnews.hk)) and (iv) on the Company’s website ([www.huamedicine.com](http://www.huamedicine.com)) on or before Thursday, September 13, 2018. The results of allocations and the Hong Kong Identity Card/passport/Hong Kong Business Registration numbers of successful applicants (where applicable) under the Hong Kong Public Offering will be available through a variety of channels from Thursday, September 13, 2018 as described in the section headed “How to Apply for the Hong Kong Offer Shares — 11. Publication of Results” in the Prospectus.



The Company will not issue temporary documents of title. No receipt will be issued for application monies received. Share certificates will only become valid at 8:00 a.m. on Friday, September 14, 2018 provided that the Global Offering has become unconditional and the right of termination described in the section headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Hong Kong Underwriting Agreement — Grounds for Termination” in the Prospectus has not been exercised. Dealings in the Shares on the Hong Kong Stock Exchange are expected to commence at 9:00 a.m. on Friday, September 14, 2018. The Shares will be traded in board lots of 500 Shares each. The stock code of the Company is 2552.

By order of the Board  
**Dr. Li Chen**  
*Chief Executive Officer and  
Executive Director*

Hong Kong, Friday, August 31, 2018

*As of the date of this announcement, the Board of Directors comprises Dr. Li Chen and Mr. George Chien Cheng Lin as executive Directors; Mr. Robert Taylor Nelsen and Dr. Lian Yong Chen as non-executive Directors; and Mr. Walter Teh-ming Kwauk, Mr. William Robert Keller, Mr. Junling Liu and Mr. Yiu Wa Alec Tsui as independent non-executive Directors.*

*Please also refer to the published version of this announcement in the **South China Morning Post** (in English).*